Melanoma patient registry for people with skin melanoma
Part of Cancer, Skin clinical trials.
This is a registry that collects information from people diagnosed with an invasive skin melanoma. It may help researchers understand who gets melanoma and how it’s diagnosed and treated over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with invasive melanoma in the skin (the primary cancer started in the skin).
- The melanoma must be a primary tumor, not a melanoma that started elsewhere.
- You must be having care at a participating hospital or clinic.
- Your diagnosis must be invasive (not only in the top surface of the skin).
- If you have melanoma that has spread and the original skin source is not known, you likely cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a future-looking database of people with melanoma in France. It collects information from consenting adults, which may help researchers better understand melanoma over time.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study is about collecting and storing tissue samples from people affected by melanoma so researchers can use them for future studies. It may help speed up research, but it is mainly about sample storage rather than testing a new treatment.
This study looks at diagnostic and prognostic factors in people who have suspicious pigmented skin lesions or melanoma that doctors are evaluating with surgery or tissue sampling. It may help improve how clinicians decide what the lesion is and what to expect over time.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study collects information from people with melanoma (skin cancer), at any stage. It may help researchers better understand melanoma and improve future care.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.